The membrane type 1 matrix metalloproteinase (MT1-MMP) has been identified as a major activator of MMP-2 -a process involving the formation of a trimolecular complex with TIMP-2. We previously identified the IGF-I receptor as a positive regulator of MMP-2 synthesis. Here, we investigated the role of IGF-IR in the regulation of MT1-MMP. Highly invasive Lewis lung carcinoma subline H-59 cells express MT1-MMP and utilize it to activate their major extracellular matrix degrading proteinase-MMP-2. These cells were transiently transfected with a plasmid vector expressing a luciferase reporter gene downstream of the mouse MT1-MMP promoter. IGF-I treatment increased luciferase activity in the transfected cells by up to 10-fold and augmented endogenous MT1-MMP mRNA and protein synthesis by up to 2-3-fold, relative to controls. MT1-MMP induction and invasion were blocked by the PI 3-kinase inhibitors LY294002 and wortmannin and by rapamycin, but not by the MEK inhibitor PD98059. Overexpression of a dominant negative Akt mutant or of the tumor suppressor phosphatase and tensin homologue, PTEN, in these cells also caused a significant reduction in MT1-MMP expression and invasion. The results demonstrate that IGF-IR controls tumor cell invasion by coordinately regulating MMP-2 expression and its MT1-MMPmediated activation and identify PI 3-kinase/Akt/mTOR signaling as critical to this regulation.
Introduction
The breakdown of the extracellular matrix (ECM) by proteinases is an essential step in the processes of cancer invasion and metastasis. Malignant progression is frequently associated with upregulated production and/or activity of one or several matrix metalloproteinases (MMPs) and these enzymes have been implicated in tumor invasion in vitro and in vivo (Johansson et al., 2000) . The 72 kDa type IV collagenase, MMP-2, plays a critical role in tumor cell invasion and in angiogenesis by facilitating the degradation of basement membrane type IV collagen. Elevated levels of this enzyme have been observed in various human malignancies (Allgayer et al., 1998; Ellenrieder et al., 2000; Hanemaaijer et al., 2000; Shimada et al., 2000; Kanayama, 2001 ) and it was identified as a target for anticancer therapy (WojtowiczPrage et al., 1997) . The MMP-2 is secreted as an inactive 72 kDa zymogen and is activated by proteolytic cleavage, extracellularly. This process involves binding to the membrane type 1 MMP (MT1-MMP) via a complex with tissue inhibitor of metalloproteinases-2 (TIMP-2) (Toth et al., 2000) . Other binding sites such as the integrin a v b 3 (Brooks et al., 1996) may also be involved. The TIMPs can also act as inhibitors of MMP-2 processing and catalytic activity when expressed in excess and their effect on MMP-2-mediated proteolysis ultimately depends on MMP-2 : TIMP ratios and the availability of MT1-MMP (Stetler-Stevenson, 2001 ). In vivo, MT1-MMP is overexpressed in malignant tissues and localized mainly in stromal cells surrounding the neoplastic cells. These peritumoral fibroblasts can be induced to overexpress MT1-MMP and consequently activate tumor cell-derived gelatinase, leading to ECM degradation (Polette and Birembaut, 1998) . In vitro, MT1-MMP expression was also observed in invasive tumor cells, possibly because they represent a late stage of tumor progression.
Recent studies have shown that MT1-MMP can also degrade the type I collagen and cleave the adhesion molecule CD44, thereby contributing to cellular invasion, directly (Kajita et al., 2001 ). MT1-MMP-deficient mice developed multiple severe connective tissue abnormalities including craniofacial dysmorphism, arthritis, osteopenia, dwarfism and fibrosis of soft tissues because of ablation of a collagenolytic activity that is essential for the assembly of skeletal and extraskeletal connective tissues. These findings identified MT1-MMP as a critical mediator of extracellular matrix turnover and connective tissue remodeling.
The receptor for the type I insulin-like growth factor (IGF-IR) and its ligands IGF-I and IGF-II play critical roles in the regulation of cellular proliferation, apoptosis and transformation. The IGFs have increasingly been recognized as important mitogens in many tumor types in vitro. Overexpression and/or constitutive activation of the IGF-IR were shown to result in the acquisition of a transformed phenotype (growth in semisolid medium) and tumorigenic potential (growth in immunodeficient nude mice) in a range of cell types (Brodt et al., 2000) . In vivo, IGF-IR-dependent tumor cell growth can be regulated in a paracrine manner, by serum or stromal cell-derived IGFs, and also through an autocrine mechanism. Increased expression of IGF-IR, IGF-I and IGF-II or a combination therefore have been documented in many animal and human malignancies (Macaulay, 1992) , and prospective clinical studies identified a high-plasma IGF-I level as a potential risk factor for carcinomas of the breast, prostate and colon (reviewed in Samani and Brodt, 2001 ). Suppression of IGF-IR or IGF expression and function, using various molecular strategies, caused a suppression of tumor cell growth and metastasis in vivo (Baserga, 1996; Samani and Brodt, 2001) , identifying this receptor/ ligand system as a target for cancer therapy (Brodt et al., 2000) .
Ligand-dependent activation of the intrinsic IGF-IR tyrosine kinase results in the phosphorylation of several substrates including the insulin receptor substrates (IRS) 1-4 and Shc (Butler et al., 1998; Petley et al., 1999) . This can trigger multiple signal transduction pathways including the MAP kinase (ERK) pathway implicated in receptor-mediated mitogenesis and transformation and the PI 3-kinase-dependent pathway implicated in the transmission of cell survival signals (Hanahan and Weinberg, 2000; Samani and Brodt, 2001 ). Activation of the catalytic subunit of PI 3-kinase results in the production of PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 and causes membrane translocation, phosphorylation and activation of the protein serine/threonine kinase Akt/ protein kinase B (PKB) -a major transducer of PI 3-kinase signal. The tumor-suppressor PTEN, a protein and lipid phosphatase, dephosphorylates the inositol ring 3 0 -OH position in PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 , thereby downregulating Akt activity. Reduced expression or inactivating mutations of PTEN resulting in increased Akt activity have been reported in various malignancies (Davies et al., 1998; Li and Sun, 1998; Weng et al., 1999) . In addition, some of the transforming, cell-growth and cell-cycle-promoting effects of PI 3-kinase are known to be mediated through the mammalian target of rapamycin mTOR and p70 S6K (Gingras et al., 2001) .
We previously identified the IGF-IR as a regulator of carcinoma cell invasion and MMP-2 synthesis and activity (Long et al., 1998a,b; Brodt et al., 2001) . Since MMP-2 activation depends on the availability and activity of MT1-MMP, it was of interest to investigate whether IGF-I plays a role in the regulation of MT1-MMP synthesis. We show here that IGF-I regulates MT1-MMP synthesis and invasion through activation of the PI 3-kinase-Akt/ mTOR pathway.
Results

IGF-I is a positive regulator of MT1-MMP, but not of TIMP-2 expression
In previous studies, we found that MMP-2 synthesis and the invasion of H-59 carcinoma cells were regulated by the IGF-IR (Long et al., 1998a,b) . Gelatin zymography revealed the presence of activated forms of MMP-2 in H-59-conditioned medium. MT1-MMP expression in these cells was therefore investigated. Using semiquantitative RT-PCR, we found that in response to 10 ng/ml IGF-I, MT1-MMP mRNA expression began to rise within 2 h, reaching maximal levels (2.9-fold) at 8 h and remaining high for up to 24 h. During the same period, TIMP-2 mRNA levels remained unchanged (Figure 1a) . Increased MT1-MMP mRNA synthesis was reflected in increased protein production that was detectable 24 h after IGF-I induction (Figure 1b ). To determine whether the effect of IGF-I on MT1-MMP transcription was direct, the tumor cells were transiently transfected with a plasmid vector expressing the full-length MT1-MMP promoter upstream of the Firefly luciferase reporter gene. To control for transfection efficiency, the cells were cotransfected with a second vector expressing the Renilla luciferase gene. When the transfected cells were treated with 10 ng/ml IGF-I for 24 h, luciferase activity (measured as the Firefly:Renilla luciferase activity ratios) increased by up to 10-fold relative to control, unstimulated cells (Figure 2 ), confirming that IGF-Imediated regulation of MT1-MMP expression was direct.
MT1-MMP is required for MMP-2 activation and H-59 invasion
To investigate the role of MT1-MMP in MMP-2 activation in this model, the cells were treated with an anti-MT1-MMP antibody, directed to the catalytic domain of the enzyme, for 48 h. This treatment blocked MMP-2 processing, as revealed by gelatin zymography (Figure 3a ) and inhibited cell invasion as revealed by the Matrigel invasion assay (Figure 3b ), confirming that MT1-MMP activity was essential for MMP-2 activation and cellular invasion of H-59 cells.
Inhibition of PI 3-kinase blocks IGF-I-induced MT1-MMP synthesis and H-59 invasion
In H-59 cells, both MAP kinase and PI 3-kinase/Akt signaling are activated in response to IGF-I (Figure 4a ). To identify the pathway(s) regulating MT1-MMP induction by IGF-I, we therefore used the corresponding, specific pharmacological inhibitors. We found that the PI 3-kinase inhibitors, LY294002 (20 mm) and wortmannin (5 nm 
IGF-I-mediated MT1-MMP induction is blocked by a dominant negative Akt and rapamycin
To analyse the role of Akt in MT1-MMP induction, the cells were transiently transfected with a plasmid vector expressing an Akt mutant with a lysine-methionine substitution in residue 179 (K 179 M) that was previously shown to have a dominant negative effect on PI 3-kinase signaling (Franke et al., 1995) . In these cells, but not in wild-type (WT) Akt-transfected controls, IGF-Imediated MT1-MMP induction and invasion were inhibited, as demonstrated by Western blotting and the Matrigel invasion assay (Figure 5a, d ). Multiple Akt substrates have been identified, among them mTOR-a kinase implicated in the regulation of protein translation through phosphorylation of the initiation factor eIF-4E and of p70 s6k . We found that pretreatment of the tumor cells with rapamycin (20 ng/ml) completely blocked IGF-I-mediated MT1-MMP induction, as assessed by Western blotting (Figure 5b ) and also inhibited IGF-Iinduced Matrigel invasion (Figure 5d ). 
Discussion
Of the four known membrane type MMPs, MT1-MMP is most often overexpressed in malignant tissue and it is frequently detected in association with the activated form of MMP-2 . Recently, it was shown that MT1-MMP can play a dual role in extracellular matrix remodeling. It can activate the proenzyme forms of MMP-2 and procollagenase 3 on the cell membrane and can also cleave directly some of the ECM proteins such as gelatin, type I collagen and fibronectin (Ohuchi et al., 1997) . TIMP-2 can serve as the link between MMP-2 and MT1-MMP, forming a cell membrane triplex required for MMP-2 activation. When expressed in excess, however, TIMP-2 can block MMP-2 activity and shift the equilibrium towards inhibition rather than enhancement of proteolysis (Stetler-Stevenson, 2001 ). We reported previously that IGF-I induces MMP-2 synthesis and here we show that it enhances MT1-MMP, but not TIMP-2 production. The concomitant regulation of MMP-2 and its activating enzyme MT1-MMP by IGF-I may provide a key mechanism for efficient production of catalytically active MMP-2, thereby optimizing matrix degradation and invasion. Our data show that the IGF-I regulates MT1-MMP synthesis by a mechanism that involves PI 3-kinase/Akt/ mTOR, but not MEK/ERK signaling. PI 3-kinase has been identified as a major transducer of the IGF-IR signal in a variety of cellular systems. Among others, its activity was shown to be critical for cell survival, a function mediated through Akt and Bax activation (Parrizas et al., 1997; Matsuzaki et al., 1999; Kermer et al., 2000) . In addition, it was also implicated in IGF-Iinduced mitogenesis (Dufourny et al., 1997; Skrtic et al., 1999) and in IGF-IR-induced synthesis of several proteins such as prolactin (Castillo et al., 1998) , HGF (Kermer et al., 2000) , type I collagen (Svegliati-Baroni et al., 1999) , and endothelial nitric oxide synthase (Michell et al., 1999) . In some of these studies, the PI 3-kinase pathway has been identified as the major transducer of the IGF-IR signal, with MAPK signaling playing a more minor, or no role (Dufourny et al., 1997) , whereas in others studies, ERK signaling was identified as the predominant pathway for transduction of the IGF-I/IGF-IR signal (Lavandero et al., 1998) . The degree to which different cells utilize common pathways to convey IGF-IR signals may be cell-context dependent and may be determined by expression levels of downstream substrates such as IRS or Shc (Bruning et al., 1997; Petley et al., 1999; Navab et al., 2001) . Recent studies suggest that EGF receptor levels may also influence which one of the signaling pathways predominates (Roudabush et al., 2000) .
Interestingly, we noted that in H-59 cells treated with the PI 3-kinase inhibitors wortmannin and LY294002, increased levels of phosphorylated ERK could be detected following IGF-I treatment (Figure 4a ). This suggests that in this model, a negative regulatory effect is exerted by the PI-3 kinase pathway on MEK/ERK signaling. This may be because of recruitment and phosphorylation of IRS-1 by Akt (Trumper et al., 2000) or due to Akt-mediated inhibition of Raf activation as reported elsewhere (Penninger and Woodgett, 2001 ). Crosstalk and reciprocal positive or negative regulation between these two pathways have been noted in other cellular systems (Blum et al., 2001; Yart et al., 2002) and their patterns appear to be growth factor-specific (Yu et al., 2002) . The decreased MT1-MMP induction observed in the treated cells, despite increased ERK regulator and PTEN as a suppressor, of tumor cell invasion Koul et al., 2001) . Studies with several glioma lines and the B-16F10 melanoma cells identified PTEN as a negative regulator of MMP-2 transcription and activity (Koul et al., 2001; Hwang et al., 2001) . Our results suggest that the PTEN effect on invasion observed in these systems may have also been linked to its role in MT1-MMP regulation. In our invasion studies, we observed that the MEK inhibitor PD98059, although it did not affect IGF-I-induced MT1-MMP synthesis, nevertheless reduced H-59 cell invasion by 30%. This may be because of the role of MEK/ERK signaling in the regulation of cell spreading and migration-processes required for invasion (Seddighzadeh et al., 1999) . Our finding raise the possibility that the synthesis of MT1-MMP and MMP-2 are functionally linked to the survival and growth functions mediated by IGF-I. Studies with MT1-MMP-deficient mice have recently highlighted the critical role that this enzyme plays in normal extracellular matrix (collagen) turnover, tissue remodeling and growth (Holmbeck et al., 1999) , functions that are also regulated by the IGF-IR/IGF axis. At the cellular level, matrix remodeling is an essential component of the survival machinery because it provides the cells with the ECM anchorage required to transmit integrin-mediated anti-apoptotic signals (Sugiyama et al., 1998) . It is conceivable, therefore, that the regulation of MT1-MMP and MMP-2 synthesis and activity by IGF-IR contribute to its role as a cell survival and growth-promoting factor.
Materials and methods
Cells and reagents
The origin and invasive/metastatic phenotype of murine Lewis lung carcinoma subline H-59 cells were described in detail previously (Brodt, 1986) . These cells are highly invasive and metastatic to the liver, two phenotypes linked to IGF-IR Regulation of MT1-MMP and invasion by IGF-1 D Zhang and P Brodt expression (Long et al., 1994; Brodt et al., 2001) . The cells were cultured in RPMI 1640 supplemented with 10% FCS. They were routinely tested for infectious agents and were found to be free of infection during the course of this study. Recombinant hIGF-I was from United States Biological (Swampscott, MA, USA). The inhibitors LY294002 and PD98059 were from Calbiochem (Darmstade, Germany) and wortmannin was from Sigma (St Louis, MI, USA).
Plasmids and transfection
The WT and dominant negative K 179 M Akt mutant (DN-Akt) constructs were kind gifts from Dr David Kaplan (Montreal Neurological Institute, Montreal, Quebec, Canada). They were described in detail elsewhere (Franke et al., 1995) . The pCEP4 plasmid expressing a full-length WT PTEN construct (Simpson et al., 2001 ) was a kind gift from Dr Nahum Sonenberg (McGill University, Montreal, Quebec, Canada). Transient transfections of H-59 cells seeded in 10 cm culture dishes at a density of 10 6 cells per dish were carried out by using 5 mg of DNA per dish and the Lipofectamine Plus Reagent (GIBCO BRL), used as suggested by the manufacturer. After a 5 h incubation in complete medium, the cells were serum-starved overnight then either incubated for 24 h with 10 ng/ml IGF-I for measurement of MT1-MMP protein or added onto the Matrigel-coated filters for the invasion assay.
Reverse transcription PCR (RT-PCR)
Total cellular RNA was extracted using the Trizol reagent (Life Technologies Inc. Burlington, Ontario, Canada). The RT-PCR was performed as described previously (Khatib et al., 1999) . The primers used were as follows: for MT1-MMP: sense 5 0 -GTG CCC TAT GCC TAC ATC CG-3 0 ; antisense 5 0 -TTG GGT ATC CGT CCA TCA CT-3 0 (expected product 580 bp) for TIMP-2; sense 5 0 -AGA CGT AGT GAT CAG GGC CA-3 0 , antisense 5 0 -GTA CCA CGC GCA AGA ACC AT-3 0 (expected product 490 bp); for GAPDH; sense 5 0 -GGT GAA GGT CGG TGT GAA CGG ATT T-3 0 , antisense-5 0 -AAT GCC AAA GTT GTC ATG GAT GAC C-3 0 (expected product 520 bp). The cDNA was amplified using 25 (GAPDH) or 35 (MT1-MMP and TIMP-2) cycles, each of 30 s at 941C, 30 s at 581C and 30 s at 721C, followed by a 10 min incubation at 721C. In the preliminary experiments, it was confirmed that under these conditions, the RT-PCR products were obtained during the exponential phase of the amplification curve. The amplified DNA fragments were analysed by electrophoresis on a 1.8% agarose gel.
Dual-luciferase reporter assay
H-59 cells were cotransfected with the pGL3-basic vector expressing the Firefly luciferase gene downstream of a 1200 bp mouse MT1-MMP promoter sequence (nucleotides À1297 to -97, Cha et al., 2001 ) and the pRL-SV-40 plasmid expressing the Renilla luciferase gene (from Promega), using the Lipofectamine Plus Reagent (Life Technologies). The transfected cells were incubated for 5 h in complete medium, and then in serumdepleted RPMI medium for 18 h. Fresh serum-free medium was then added, with or without 10 ng/ml hIGF-I, for an additional incubation as indicated. Firefly luciferase and Renilla luciferase activities were analysed by the DualLuciferase Reporter Assay System (from Promega).
Immunoblotting
Subconfluent monolayers of the tumor cells (approximately 8 Â 10 6 cells) were washed extensively to remove serum and the cells cultured overnight in serum-free medium. For detection of MT1-MMP, the cells were then incubated with 10 ng/ml hIGF-I for 24 h, washed with ice-cold PBS and solubilized in 1 ml lysis buffer containing 30 mm Tris-HCL (pH 8.0); 1% Triton X-100; 150 mm NaCl; 1 mm Na 3 VO 4 ; 1 mm NaF; 1 mm iodoacetamide; 0.5% deoxycholic acid, sodium salt; 1 mm PMSF and 0.01% aprotinin. Proteins (100 mg/lane) were separated on a 10% SDS-PAGE, transferred onto nitrocellulose membranes and probed with a monoclonal anti-MT1-MMP antibody (from Calbiochem, MA, USA). For the detection of Akt and phospho-Akt (pT308), MAP kinase and phospho-MAP kinase, H-59 cells were incubated with hIGF-I (10 ng/ml) for 10 min and the cell lysates were assayed by Western blotting using the corresponding antibodies (New England Biolabs, Beverly, MA, USA). Proteins were detected with a Lumi-Light Western Blotting Substrate (Roch Diagnostics, Mannheim, Germany) following incubation with the appropriate horseradish peroxidase-conjugated secondary antibodies. The blots were stripped and reprobed with antityrosine tubulin antibody (Sigma). The Tubulin band was used to normalize the data.
Gelatin zymography
The gelatinolytic activity of MMP-2 was analysed by gelatin zymography, as we described previously (Brodt et al., 1992) . Concentrated conditioned media (50 Â ) were electrophoresed on a 10% SDS-PAGE containing 1 mg/ml gelatin. The gels were stained with Comassie Blue R250 and destained with 10% acetic acid-20% methanol until the desired color intensity was obtained. The gelatinolytic activity, seen as a clear zone on the blue background was quantified by laser densitometry using photographic negatives of the gels.
Cell invasion assay
Tumor cell invasion was measured using reconstituted basement membrane (Matrigel), as we previously described (Long et al., 1998a) . Matrigel was used at a concentration of 0.23 mg/ ml, 5 Â 10 4 cells were added to the upper chamber and 50 ng/ml hIGF-I were used in the lower chamber to induce cell migration. When inhibitors (or antibody) were used, the cells were preincubated with the inhibitors at the indicated concentrations for 5 h and were added to the Matrigel with the same inhibitors (or antibody) for 48 h at 371C. Triplicate filters were used for each treatment and all the cells on each filter were counted using an inverted microscope (Diaphot-TMD, Nikon, Mississauga, Ontario, Canada).
Cell viability assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to analyse the effect of the inhibitors on cell viability. H-59 cells were cultured overnight in 24-well plates (10 5 cells/well) containing complete medium, washed and cultured in serum-free medium containing or not, 10 ng/ml hIGF-I and inhibitors. At different time intervals, the medium was aspirated and 200 ml of the MTT reagent (1 mg/ ml) were added to each well for 1 h at 371C. After addition of 200 ml DMSO, the OD was measured at 550 nm using a microplate reader (Molecular Devices). In parallel, viable cells were also enumerated using the trypan blue exclusion dye. Dr Motohalu Seiki for the MT1-MMP promoter construct and Dr Nahum Sonenberg for the PTEN plasmid as well as for helpful discussions. We thank Mrs Lucia Fallavollita and Mr Tarek Boutros for excellent technical assistance and Drs Amir A Samani and Eric Chevet for helpful discussions. This study was supported by a grant from the Canadian Institute for Health Research to PB.
